SV2004001560A - Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age - Google Patents

Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age

Info

Publication number
SV2004001560A
SV2004001560A SV2003001560A SV2003001560A SV2004001560A SV 2004001560 A SV2004001560 A SV 2004001560A SV 2003001560 A SV2003001560 A SV 2003001560A SV 2003001560 A SV2003001560 A SV 2003001560A SV 2004001560 A SV2004001560 A SV 2004001560A
Authority
SV
El Salvador
Prior art keywords
diabetic
treatment
diseases
nephropatia
metabolic diseases
Prior art date
Application number
SV2003001560A
Other languages
English (en)
Inventor
Stefan Schafer
Wolfgang Linz
Markus Bleich
Jochen Huber
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of SV2004001560A publication Critical patent/SV2004001560A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

USO DE INHIBIDORES DE VASOPEPTIDASA DE LA FORMULA (I) PARA EL TRATAMIENTO Y/O PROFILAXIS DE NEFROPATIA EN PACIENTES DIABETICOS O NO DIABETICOS, INCLUIDA LA NEFROPTIA DIABETICA O NO DIABETICA , GLOMERULONEFRITIS , ESCLEROSIS GLOMERULAR , SINDROME NEFROTICO, NEFROESCLEROSIS HIPERTENSIVA, MICROALBUMINURIA O ENFERMEDAD RENAL DE FASE TERMINAL, O RESISTENCIA A LA INSULINA O DE ENFERMEDADES METABOLICAS ASOCIADAS CON PRODUCTOS FINALES, DE GLICACION AVANZADA TALES COMO COMPLICACIONES DIABETICAS, NEUROPATIA DIABETICA, NEFROPATIA DIABETICA , RETINOPATIA DIABETICA, CATARATAS, INFARTO DE MIOCARDIO Y/O CARDIOMIOPATIA DIABETICA , O ATEROSCLEROSIS O DISFUNCION ENDOTELIAL.
SV2003001560A 2002-06-28 2003-06-23 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age SV2004001560A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen

Publications (1)

Publication Number Publication Date
SV2004001560A true SV2004001560A (es) 2004-02-26

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001560A SV2004001560A (es) 2002-06-28 2003-06-23 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age

Country Status (39)

Country Link
US (2) US6930103B2 (es)
EP (1) EP1519732B1 (es)
JP (1) JP4564354B2 (es)
KR (1) KR101072235B1 (es)
CN (1) CN100366254C (es)
AR (1) AR040343A1 (es)
AT (1) ATE548040T1 (es)
AU (1) AU2003280440B2 (es)
BR (1) BR0312250A (es)
CA (1) CA2490277C (es)
CR (1) CR7667A (es)
CY (1) CY1112905T1 (es)
DE (1) DE10229180A1 (es)
DK (1) DK1519732T3 (es)
EC (1) ECSP045513A (es)
ES (1) ES2383889T3 (es)
HK (1) HK1079435A1 (es)
HN (1) HN2003000193A (es)
HR (1) HRP20041212B1 (es)
IL (2) IL165935A0 (es)
MA (1) MA27281A1 (es)
MX (1) MXPA04012230A (es)
NO (1) NO334811B1 (es)
NZ (1) NZ537480A (es)
OA (1) OA12871A (es)
PA (1) PA8576501A1 (es)
PE (1) PE20040582A1 (es)
PL (1) PL218070B1 (es)
PT (1) PT1519732E (es)
RS (1) RS52478B (es)
RU (1) RU2336080C2 (es)
SI (1) SI1519732T1 (es)
SV (1) SV2004001560A (es)
TN (1) TNSN04262A1 (es)
TW (1) TWI326215B (es)
UA (1) UA82845C2 (es)
UY (1) UY27869A1 (es)
WO (1) WO2004002492A1 (es)
ZA (1) ZA200409382B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP2558208B2 (ja) * 1991-03-01 1996-11-27 ゼリア新薬工業株式会社 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
ES2117123T3 (es) * 1992-02-14 1998-08-01 Merrell Pharma Inc Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina.
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUT75160A (en) * 1994-03-24 1997-04-28 Merrell Pharma Inc Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
DE69630465T2 (de) 1995-12-27 2004-07-22 Mitsubishi Pharma Corp. Vorsorge-/heilmittel fur die komplikationen von diabetes
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
MXPA03008613A (es) * 2001-04-12 2003-12-08 Aventis Pharma Gmbh Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso.
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
AU2003280440B2 (en) 2009-07-16
ES2383889T3 (es) 2012-06-27
MXPA04012230A (es) 2005-02-25
TNSN04262A1 (en) 2007-03-12
PT1519732E (pt) 2012-05-22
WO2004002492A1 (en) 2004-01-08
IL165935A0 (en) 2006-01-15
US20040058911A1 (en) 2004-03-25
ECSP045513A (es) 2005-03-10
OA12871A (en) 2006-09-15
CN1665512A (zh) 2005-09-07
CY1112905T1 (el) 2016-04-13
EP1519732A1 (en) 2005-04-06
NO334811B1 (no) 2014-06-02
SI1519732T1 (sl) 2012-05-31
US20050171090A1 (en) 2005-08-04
US6930103B2 (en) 2005-08-16
HRP20041212B1 (hr) 2013-06-30
PL372992A1 (en) 2005-08-08
DK1519732T3 (da) 2012-06-18
MA27281A1 (fr) 2005-04-01
UY27869A1 (es) 2003-12-31
RS100704A (en) 2007-02-05
DE10229180A1 (de) 2004-01-29
NZ537480A (en) 2005-11-25
IL165935A (en) 2010-12-30
JP4564354B2 (ja) 2010-10-20
KR20050013642A (ko) 2005-02-04
TWI326215B (en) 2010-06-21
CA2490277C (en) 2011-11-01
TW200406214A (en) 2004-05-01
HN2003000193A (es) 2004-10-27
CN100366254C (zh) 2008-02-06
HRP20041212A2 (en) 2005-06-30
RS52478B (en) 2013-02-28
PL218070B1 (pl) 2014-10-31
ATE548040T1 (de) 2012-03-15
KR101072235B1 (ko) 2011-10-12
CA2490277A1 (en) 2004-01-08
AR040343A1 (es) 2005-03-30
NO20050425L (no) 2005-01-25
PA8576501A1 (es) 2004-02-07
JP2005533815A (ja) 2005-11-10
BR0312250A (pt) 2005-04-26
PE20040582A1 (es) 2004-10-18
UA82845C2 (en) 2008-05-26
US7514423B2 (en) 2009-04-07
CR7667A (es) 2005-06-16
HK1079435A1 (en) 2006-04-07
RU2336080C2 (ru) 2008-10-20
RU2005102087A (ru) 2005-07-10
EP1519732B1 (en) 2012-03-07
AU2003280440A1 (en) 2004-01-19
ZA200409382B (en) 2006-01-25

Similar Documents

Publication Publication Date Title
Rosenstock et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MX2007003161A (es) Derivado de triazol o una sal del mismo.
WO2003033524A3 (en) Peptidyl ketones as inhibitors of dpiv
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
DE602005014341D1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
MEP6908A (xx) Piridin -4-ilmetilamida za borbu protiv štetočina
MXPA05013734A (es) Hexahidropiroisoquinolinas como inhibidores de dpp-iv.
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
WO2007009389A3 (fr) Derives de propanamide substitues, preparation et utilisation de ces derives
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
MX2008004734A (es) Composicion rica en leucina.
MY183793A (en) Pharmaceutical compositions
MX2010006565A (es) Derivados de benzimidazol sustituido por carboxilo o hidroxilo.
NO20084321L (no) Triazolderivat eller salt derav
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
RS52629B (en) LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT
MXPA06012206A (es) Composicion farmaceutica ozonizada y metodos.
SV2004001560A (es) Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age
NO20034171L (no) Biguanidderivater
MY160300A (en) Acylbenzene derivative

Legal Events

Date Code Title Description
FC Refusal